Announced at HFMA 2025 Annual Meeting, the Client-Rated Tech Rankings Highlight Top Performers in Denials, Forecasting, Risk Stratification, and Claims Accuracy Based on 11,550 RCM User Evaluations
Read More
As blood sugar support becomes a top wellness priority in 2025, this comprehensive breakdown explores Sugar Defender's plant-based formula, usage protocols, and integration strategies for sustainable glucose management.
Read More
RevSpring, CarePayment, and Knowtion Health Recognized for Excellence in Patient Financial Technologies in Rankings Announced Today at HFMA ANI Conference
Read More
Rankings unveiled at HFMA Annual National Institute in Denver spotlight leading software solutions for Clearinghouse, Denial Management, and Claim Adjudication across hospitals and physician organizations
Read More
Now available in 3-, 6-, and 12-month plans, Ereforce combines eight traditional botanicals - including Ginseng, Tribulus, and Saw Palmetto - in a GMP-certified formula designed to support male vitality, circulation, and wellness integration in 2025.
Read More
New 1,150km transmission line proposes to link Angola and the DRC
HYDRO-LINK and Mitrelli join forces to deliver cross-border clean energy
U.S. investment to secure DRC critical mineral and rare earth production
Healthcare Finance Leaders Identify Top Software Solutions Across U.S. Hospital Segments Based on Real-World Results, ROI, and Financial Outcomes
Read More
New Liquid Nootropic Supplement Combines Clinically Studied Botanicals to Address Brain Fog, Enhance Focus, and Support Cognitive Health in Adults Seeking Natural Memory Solutions
Read More
U.S. Vendors Accelerate Global Growth, Addressing Increasingly Complex Private Healthcare Markets in Canada, Australia, UK, Germany, and Beyond; Updated 2025 Analysis Released at HFMA ANI Conference
Read MoreEnrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%
As recently announced, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
Read MoreTerm loan maturity extended by 12 months to June 2029
Principal balance on term loan expanded to $13.0 million from $11.1 million currently
Expanded revolving line of credit facility by $1.5 million
Expanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025
Read More-- Record annual revenue of $145.8 million, up 24.4 percent from prior year --
Fiscal Fourth Quarter Highlights
Gross profit increases to $5.2 million from $1.5 million a year ago.
Gross margin increases to 17.9 percent from 7.0 percent a year ago.
Revenue rises 35.6 percent to $29.3 million, despite approximately $3-4 million of shipments deferred to first quarter of fiscal 2026, due to delays at Haifa port.
Watch the Senate hearing: https://dai.ly/x9j0le4
Despite MMJ's full regulatory compliance and orphan drug status from the FDA, its DEA manufacturing registration (GROW MARIJUANA) remains stonewalled inside a DEA administrative court system now deemed unconstitutional under Axon and Jarkesy. Meanwhile, tribal transit networks face virtually no enforcement-exposing a hypocritical and dangerous DEA double standard.
Read More